NOVEL RECOMBINANT ADENOVIRUS VACCINE VECTORS FOR HIV/SIV IN RHESUS MONKEYS

用于恒河猴 HIV/SIV 的新型重组腺病毒疫苗载体

• 批准号: 8357920
• 负责人: Dan H. Barouch
• 金额: $ 6.84万
• 依托单位: HARVARD MEDICAL SCHOOL
• 依托单位国家: 美国
• 财政年份: 2011
• 资助国家: 美国
• 起止时间: 2011-05-01 至 2012-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8357920
• 关键词: Address; Adenovirus Vector; Adenoviruses; Antigens; Funding; Grant; HIV; HIV-1; Immune; Macaca mulatta; National Center for Research Resources; New England; Primates; Principal Investigator; Recombinants; Research; Research Infrastructure; Resources; SIV; Serotyping; Source; United States National Institutes of Health; Vaccines; Virus; base; cost; next generation; novel; vector; vector vaccine; vector-based vaccine

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. Primary support for the subproject and the subproject's principal investigator may have been provided by other sources, including other NIH sources. The Total Cost listed for the subproject likely represents the estimated amount of Center infrastructure utilized by the subproject, not direct funding provided by the NCRR grant to the subproject or subproject staff. Next generation HIV-1 vaccines will require more potent vectors as well as antigens that address the challenge of global virus diversity. We have therefore developed novel replication-incompetent adenovirus vector-based vaccines derived from rare adenovirus serotypes as well as mosaic HIV-1 antigens to expand cellular immune breadth and depth.

这个子项目是许多利用资源的研究子项目之一 由NIH/NCRR资助的中心拨款提供。子项目的主要支持 而子项目的主要调查员可能是由其他来源提供的， 包括其它NIH来源。 列出的子项目总成本可能 代表子项目使用的中心基础设施的估计数量， 而不是由NCRR赠款提供给子项目或子项目工作人员的直接资金。 下一代HIV-1疫苗将需要更有效的载体和抗原来应对全球病毒多样性的挑战。因此，我们已经开发了新的基于复制缺陷型腺病毒载体的疫苗，其来源于罕见的腺病毒血清型以及嵌合型HIV-1抗原，以扩大细胞免疫的广度和深度。